Think MCI Polak............
As mentioned before....therapeutic benefit.......MCI very large untapped market. Bring it on.
Bring it on........BooooYaaaaaaah!!
Inositol Stereoisomer Prevents Alzheimer's-Related Memory Impairment in Mice
NEW YORK (Reuters Health) Jan 24 - Scyllo-inositol (AZD-103) prevents deficits in memory caused by amyloid-beta oligomers that are associated with Alzheimer's disease, according to the results of a report in the December 2006 Annals of Neurology.
Small oligomers of amyloid-beta appear capable of interfering with hippocampal synaptic function and memory, the authors explain, and recent work suggests that stereoisomers of inositol can render these oligomers stable in small, nonfibrillar complexes.
Dr. Dennis J. Selkoe from Harvard Medical School and Brigham and Women's Hospital, Boston, and associates investigated the mechanism behind scyllo-inositol's neutralization of the acutely toxic effects of amyloid-beta on synaptic function and memory recall in mice.
Incubation of amyloid-beta oligomers with scyllo-inositol before adding them to hippocampal slices prevented the inhibition of long-term potentiation seen with untreated soluble amyloid-beta protein oligomers, the authors report. However, scyllo-inositol was ineffective after the slices had been exposed to amyloid-beta.
Scyllo-inositol also proved effective when applied directly to cells that secreted amyloid-beta, the researchers note, indicating that it not only neutralized pre-existing amyloid-beta oligomers, but also provided an additional benefit when applied directly to cells during oligomer generation and secretion.
Additional experiments showed that scyllo-inositol did not appear to interfere with amyloid-beta synthesis or oligomerization, but rather bound to and neutralized the oligomers at the time of their formation.
In a mouse model, treatment with scyllo-inositol prevented reference memory errors induced by amyloid-beta protein oligomers, the report indicates.
"Taken together," the authors conclude, "our findings provide evidence that AZD-103 neutralizes the neurotoxic activity of soluble amyloid-beta oligomers."
"Many features of scyllo-inositol, including its small size, neutral pH, stability, stereo-selectivity, and favorable toxicity profile, make it a highly attractive candidate to test for therapeutic benefit in Alzheimer disease," the investigators conclude.
Ann Neurol 2006;60:668-676.
https://www.medscape.com/viewarticle/551207